PharmaClick’s Post

Tomorrow (April 16) is the last day to apply to the next CQDM Connect-Pharma Pitch Day event. Our 4th call for ideas will focus on ''Obesity & Metabolic Disorders: Novel Targets and Drugs''. CQDM is searching for world-class research to develop novel and efficient approaches for obesity and metabolic disorders therapeutics to present to domain experts from leading global pharmaceutical organizations on May 23, 2024. Our objective is to bring ground-breaking, innovative Canadian research to CQDM’s pharmaceutical members and facilitate interactions between our pharma members and the Canadian ecosystem. Collaborative projects developed with a CQDM pharmaceutical member are eligible to obtain funding via CQDM’s Quantum Leap program. We invite passionate Canadian researchers and visionary teams to submit innovative ideas that have the potential to transform the landscape of medicine and improve patient outcomes.  Please contact Simon Fournier, MSc, MBA at [email protected] for more information or consult our website at: https://lnkd.in/gVCRiusQ #lifesciences #biotechnology #drugdevelopment #innovation #funding #projects #medical #research #intelligenceartificielle #artificialintelligence #pharmaceutique #pharmaceutical #biopharma #biopharmaceutical #rna #rnatherapeutics #arn #faciliterinnovationbiopharma #financement #connectpharma

Knowledge is Power' PharmaClick recognises this, and is once again at your service.   'Pharma Quick', an initiative by PharmaClick, is your daily dose of Industry Specific & Business critical News at the ease of your fingertips.   Get ready to be at the forefront of industry trends with Pharma Quick.   Stay informed, Stay Ahead!!   Download the App today for a detailed Read.   Available on play store and app store.       #PharmaClick #pharma #Pharmablogs #blogs #pharmacology #pharmaceuticals #pharmacystudents #pharmaprofessionals #pharmaindustry #marketplace #PharmaApp #Appforpharma #healthcare #health #biotechnology #pharmajobs #pharmaceuticalindustry #usfda Lupin Bristol Myers Squibb 2seventy bio Takeda Onco360 Oncology Pharmacy GSK Wipro Nvidia Partner Immunic Therapeutics GE HealthCare IONIC Health Genentech BioCryst Pharmaceuticals, Inc.

Exciting developments in the weight loss industry! Novo Nordisk and Eli Lilly are leading the charge, with projections suggesting a potential $200 billion global market within the next decade. Innovative drugs like Wegovy and Zepbound are transforming weight management, leveraging decades-old diabetes treatments. AstraZeneca and Pfizer are entering the arena, exploring oral GLP-1 agonists for greater accessibility. The race continues with Lilly's retatrutide showing promising results, and companies like Novo and Lilly strategically acquiring products to address side effects and enhance health benefits. A dynamic landscape to watch in the coming years! #WeightLoss #PharmaInnovation #csuitepharma

Apply to the next CQDM Connect-Pharma Pitch Day event before April 16, 2024. Our 4th call for ideas will focus on ''Obesity & Metabolic Disorders: Novel Targets and Drugs''. CQDM is searching for world-class research to develop novel and efficient approaches for obesity and metabolic disorders therapeutics to present to domain experts from leading global pharmaceutical organizations on May 23, 2024. Our objective is to bring ground-breaking, innovative Canadian research to CQDM’s pharmaceutical members and facilitate interactions between our pharma members and the Canadian ecosystem. Collaborative projects developed with a CQDM pharmaceutical member are eligible to obtain funding via CQDM’s Quantum Leap program. We invite passionate Canadian researchers and visionary teams to submit innovative ideas that have the potential to transform the landscape of medicine and improve patient outcomes.  Please contact Simon Fournier, MSc, MBA at [email protected] for more information or consult our website at: https://lnkd.in/gVCRiusQ #lifesciences #biotechnology #drugdevelopment #innovation #funding #projects #medical #research #intelligenceartificielle #artificialintelligence #pharmaceutique #pharmaceutical #biopharma #biopharmaceutical #rna #rnatherapeutics #arn #faciliterinnovationbiopharma #financement #connectpharma

Macrocyclic drugs are transforming healthcare with their ability to target complex protein interactions, a feat beyond the reach of traditional small molecule drugs. By combining the potency of small molecules with biological specificity, they are opening new avenues in the treatment of complex diseases. These drugs are synthesized using advanced techniques like solid-phase synthesis and click chemistry, representing significant strides in pharmaceutical science. These methods not only enhance drug development but also signal a new era in healthcare advancement. Key Insights for Healthcare Professionals: 1. Macrocyclic drugs represent a groundbreaking advancement, offering novel solutions to intricate medical challenges. 2. The development of these drugs showcases the growing sophistication and capabilities within pharmaceutical research. 3. This innovation stands as a significant milestone in medicine, with the potential to revolutionize patient care and therapeutic strategies. #Chemistry #DrugDevelopment #ClinicalResearch

Speed up the Drug Development Process With Fit-for-Purpose #Metabolite Identification Solutions -- Read about it on the #AnalyteGuru blog. https://lnkd.in/dbbYAtJk #pharmaceutical #biopharmaceutical #MetID #drugdevelopment

Apply to the next CQDM Connect-Pharma Pitch Day event before April 16, 2024. Our 4th call for ideas will focus on ''Obesity & Metabolic Disorders: Novel Targets and Drugs''. CQDM is searching for world-class research to develop novel and efficient approaches for obesity and metabolic disorders therapeutics to present to domain experts from leading global pharmaceutical organizations on May 23, 2024. Our objective is to bring ground-breaking, innovative Canadian research to CQDM’s pharmaceutical members and facilitate interactions between our pharma members and the Canadian ecosystem. Collaborative projects developed with a CQDM pharmaceutical member are eligible to obtain funding via CQDM’s Quantum Leap program. We invite passionate Canadian researchers and visionary teams to submit innovative ideas that have the potential to transform the landscape of medicine and improve patient outcomes.  Please contact Simon Fournier, MSc, MBA at [email protected] for more information or consult our website at: https://lnkd.in/gVCRiusQ #lifesciences #biotechnology #drugdevelopment #innovation #funding #projects #medical #research #intelligenceartificielle #artificialintelligence #pharmaceutique #pharmaceutical #biopharma #biopharmaceutical #rna #rnatherapeutics #arn #faciliterinnovationbiopharma #financement #connectpharma

Apply to the next CQDM Connect-Pharma Pitch Day event before April 16, 2024. Our 4th call for ideas will focus on ''Obesity & Metabolic Disorders: Novel Targets and Drugs''. CQDM is searching for world-class research to develop novel and efficient approaches for obesity and metabolic disorders therapeutics to present to domain experts from leading global pharmaceutical organizations on May 23, 2024. Our objective is to bring ground-breaking, innovative Canadian research to CQDM’s pharmaceutical members and facilitate interactions between our pharma members and the Canadian ecosystem. Collaborative projects developed with a CQDM pharmaceutical member are eligible to obtain funding via CQDM’s Quantum Leap program. We invite passionate Canadian researchers and visionary teams to submit innovative ideas that have the potential to transform the landscape of medicine and improve patient outcomes.  Please contact my friendly colleague Simon Fournier, MSc, MBA at [email protected] for more information or consult our website at: https://lnkd.in/en3McWuT #lifesciences #biotechnology #drugdevelopment #innovation #funding #projects #medical #research #intelligenceartificielle #artificialintelligence #pharmaceutique #pharmaceutical #biopharma #biopharmaceutical #rna #rnatherapeutics #arn #faciliterinnovationbiopharma #financement #connectpharma

𝐆𝐥𝐨𝐛𝐚𝐥 𝐇𝐢𝐠𝐡 𝐏𝐨𝐭𝐞𝐧𝐜𝐲 𝐀𝐏𝐈 𝐂𝐃𝐌𝐎𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐞𝐭 𝐟𝐨𝐫 𝐒𝐭𝐫𝐢𝐤𝐢𝐧𝐠 𝐆𝐫𝐨𝐰𝐭𝐡 𝐛𝐲 2027 To learn more about the research, fill out a quick inquiry for a sample report: https://lnkd.in/dcekvxpp The Global High Potency API CDMOs Market is expected to witness a high and a single-digit growth by 2027. The principal factors fueling the market’s growth are growing demand for oncology medications, innovations in manufacturing technology, and the strong pipeline of small molecule highly potent drug products in the development stage. Additionally, the growing utilization of targeted therapies for addressing chronic diseases is anticipated to further fuel the global market’s growth. 𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬: 𝐇𝐢𝐠𝐡 𝐏𝐨𝐭𝐞𝐧𝐜𝐲 𝐀𝐏𝐈 𝐂𝐃𝐌𝐎𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 Some of the key and established players operating in the global high potency API CDMOs market are Lonza, Sanofi, Pfizer, Novartis, Roche, Bristol Myers Squibb, Bayer HealthCare Manufacturing S.r.l., Merck Group. and WuXi STA, a subsidiary of WuXi AppTec among others. See full list and more industry insights: https://lnkd.in/dXwpm6UC #Pharmaceuticals #CDMOs #HighPotencyAPI #MarketTrends #InnovationLeaders #HighPotencyAPI #PharmaceuticalIndustry #MarketGrowth #GlobalHealthcare #Biotech #OncologyMedications #ManufacturingTechnology #TargetedTherapies #Biopharmaceuticals #CompetitiveLandscape #IndustryInsights #DrugDevelopment #HealthcareInnovation #LeadershipSpotlight #MarketTrends #GlobalMarket #BiopharmaLeaders #FutureOfMedicine #HPAPIs #HPAPICDMOs #Manufacturing #Pharma

Great to have you at euroPLX 85 Dublin José Miguel Dias, Gonçalo Rocha and Bluepharma. #europlx #raucon #businessdevelopment #business #development #event #sales #events #tips #tip #partnering #success #pro #networking #network #pharma #pharmaceutical #opportunities #businessopportunities #networkingevent #benchmark